Friday 16 May 2014 3:25pm
New Zealanders taking a higher dose of simvastatin, one of the statin drugs used to prevent heart attacks and strokes, have a greater risk of rhabdomyolysis than people taking a lower dose according to new University of Otago research. However the condition, in which breakdown of muscle tissue can lead to acute kidney failure, is still very rare in both groups.
In a new study published in the journal International Journal of Cardiology, the researchers found that people taking 40mg of simvastatin daily were about five times as likely to develop rhabdomyolysis when compared with people taking 20mg daily.
In absolute terms, the risks were about 11 per 100,000 person-years in people taking 40mg simvastatin and 2 per 100,000 person-years in those taking 20mg.
Study lead investigator Dr Lianne Parkin says recent meta-analyses have clearly shown that the benefits of statins in preventing major cardiovascular events far outweigh any serious adverse effects associated with their use.
“However, these meta-analyses were based on highly selected participants in randomised controlled trials and there was very little information about the risk of rhabdomyolysis in people taking the doses of simvastatin that are recommended for use in New Zealand,” Dr Parkin says.
“While previous research has found a greater risk of serious muscle damage in people taking higher doses of statins, our study is the largest investigation to date of rhabdomyolysis in a general population of simvastatin users and the first to provide separate estimates of risk for 40mg and 20mg simvastatin.”
The researchers used routinely collected health and prescription medicine data to conduct a study based on 313,552 people of all ages who were dispensed simvastatin at any time between 2005 and 2009. Other factors, including age, sex, medical conditions, and other prescription drugs, were taken into account in the analyses.
“Statins are one of the most widely used classes of drugs,” says Dr Parkin, “and it is reassuring to have found a very low risk of rhabdomyolysis in New Zealanders using simvastatin. The greater risk associated with the use of 40mg simvastatin is one of several factors which patients and their doctors might consider when discussing the balance of benefits and risks of cholesterol-lowering treatment, and the most appropriate dose and type of statin to be used.”
The research was funded by Medsafe and the Health Research Council of New Zealand.
For more information, contact:
Dr Lianne Parkin
Department of Preventive and Social Medicine
Dunedin School of Medicine
University of Otago
Tel 64 3 479 8425
Parkin L, Paul C, Herbison GP. Simvastatin dose and risk of rhabdomyolysis: Nested case-control study based on national health and drug dispensing data.
A list of Otago experts available for media comment is available elsewhere on this website.
Electronic addresses (including email accounts, instant messaging services, or telephone accounts) published on this page are for the sole purpose of contact with the individuals concerned, in their capacity as officers, employees or students of the University of Otago, or their respective organisation. Publication of any such electronic address is not to be taken as consent to receive unsolicited commercial electronic messages by the address holder.